An improved radiolabelled RNA aptamer molecule for HER2 imaging in cancers

References

• Amler LC, Wang Y, Hampton G. HER2 as a therapeutic target in ovarian cancer. In: Farghaly SA, ed. Ovarian cancer -- clinical and therapeutic perspectives. Rijeka, Croatia: In Tech; 2012:289–304
   Google Scholar
• Santarius T, Shipley J, Brewer D, et al. A census of amplified and overexpressed human cancer genes. Nat Rev Cancer 2010;10:59–64
   PubMed Web of Science ®Google Scholar
• Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharmaceut Design 2008;14:2999–3019
   PubMed Web of Science ®Google Scholar
• Cho H-S, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756–60
   PubMed Web of Science ®Google Scholar
• Hermann T, Patel DJ. Adaptive recognition by nucleic acid aptamers. Science 2000;287:820–5
   PubMed Web of Science ®Google Scholar
• Jayasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 1999;45:1628–50
   PubMed Web of Science ®Google Scholar
• Song KM, Lee S, Ban C. Aptamers and their biological applications. Sensors 2012;12:612–31
   PubMed Web of Science ®Google Scholar
• Bast RC Jr, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncology 2001;19:1865–78
   PubMed Web of Science ®Google Scholar
• Engfeldt T, Orlova A, Tran T, et al. Imaging of HER2-expressing tumours using a synthetic affibody molecule containing the Tc-99m-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging 2007;34:722–33
   PubMed Web of Science ®Google Scholar
• Hnatowich DJ, Mardirossian G, Rusckowski M, et al. Directly and indirectly technetium-99m-labeled antibodies – a comparison of in vitro and animal in vivo properties. J Nucl Med 1993;34:109–19
   PubMed Web of Science ®Google Scholar
• King R, Surfraz MB, Finucane C, et al. 99mTc-HYNIC-gastrin peptides: assisted coordination of 99mTc by amino acid side chains results in improved performance both in vitro and in vivo. J Nucl Med 2009;50:591–8
   PubMed Web of Science ®Google Scholar
• Fu P, Shen B, Zhao C, et al. Molecular imaging of MDM2 messenger RNA with 99mTc-labeled antisense oligonucleotides in experimental human breast cancer xenografts. J Nucl Med 2010;51:1805–12
   PubMed Web of Science ®Google Scholar
• Decristoforo C, Mather SJ. 99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution. Nucl Med Biol 1999;26:389–96
   PubMed Web of Science ®Google Scholar
• Decristoforo C, Mather SJ. Technetium-99m somatostatin analogues: effect of labelling methods and peptide sequence. Eur J Nucl Med 1999;26:869–76
   PubMedGoogle Scholar
• Hernandez-Cairo A, Perera-Pintado A, Prats-Capote A, et al. Comparative study of the biodistribution of (99m)Tc-HYNIC-Lys3-Bombesin obtained with the EDDA/tricine and NA/tricine as coligands. Rev Esp Med Nucl Imagen Mol 2012;31:61–5
   Web of Science ®Google Scholar
• Varmira K, Hosseinimehr SJ, Noaparast Z, Abedi SM. An HER2-targeted RNA aptamer molecule labeled with 99mTc for single-photon imaging in malignant tumors. Nucl Med Biol 2013. [Epub ahead of print]. doi: 10.1016/j.nucmedbio.2013.07.004
   Google Scholar
• Persson M, Tolmachev V, Andersson K, et al. [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur J Nucl Med Mol Imaging 2005;32:1457–62
   PubMed Web of Science ®Google Scholar
• Ruckman J, Green LS, Beeson J, et al. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998;273:20556–67
   PubMed Web of Science ®Google Scholar
• Dupont DM, Madsen JB, Hartmann RK, et al. Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding. RNA 2010;16:2360–9
   PubMed Web of Science ®Google Scholar
• Tolmachev V, Stone-Elander S, Orlova A, et al. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol 2010;11:992–1000
   PubMed Web of Science ®Google Scholar
• Wallberg H, Orlova A, Altai M, et al. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties. J Nucl Med 2011;52:461–9
   PubMed Web of Science ®Google Scholar
• Goldstein R, Sosabowski J, Vigor K, et al. Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer. Expert Rev Anticancer Ther 2013;13:359–73
   PubMed Web of Science ®Google Scholar
• Nayak TK, Bernardo M, Milenic DE, et al. Orthotopic pleural mesothelioma in mice: SPECT/CT and MR imaging with HER1- and HER2-targeted radiolabeled antibodies. Radiology 2013;267:173–82
   PubMed Web of Science ®Google Scholar
• King RC, Surfraz MB, Biagini SC, et al. How do HYNIC-conjugated peptides bind technetium? Insights from LC-MS and stability studies. Dalton Trans 2007;43:4998–5007
   PubMedGoogle Scholar
• Liu N, Ding H, Zhu Z, et al. Radiolabeling small RNA with technetium-99m for visualizing cellular delivery and mouse biodistribution. Nucl Med Biol 2007;34:399–404
   PubMed Web of Science ®Google Scholar
• Decristoforo C, Melendez-Alafort L, Sosabowski JK, et al. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide. J Nucl Med 2000;41:1114–19
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783–91
   PubMed Web of Science ®Google Scholar
• Weinberg WC, Frazier-Jessen MR, Wu WJ, et al. Development and regulation of monoclonal antibody products: challenges and opportunities. Cancer Metastasis Rev 2005;24:569–84
   PubMed Web of Science ®Google Scholar
• Samaranayake H, Wirth T, Schenkwein D, et al. Challenges in monoclonal antibody-based therapies. Ann Med 2009;41:322–31
   PubMed Web of Science ®Google Scholar
• Lub-de Hooge MN, Kosterink JG, Perik PJ, et al. Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol 2004;143:99–106
   PubMed Web of Science ®Google Scholar
• Hosseinimehr SJ, Tolmachev V, Orlova A. Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design. Drug Discov Today 2012;17:1224–32
   PubMed Web of Science ®Google Scholar